• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用由维生素 A 支架脂质类似物组成的脂质纳米颗粒向肝星状细胞递送小干扰 RNA。

The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material.

机构信息

Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.

NOF Corporation, 3-3 Chidori-cho, Kawasaki-ku, Kawasaki, Kanagawa 210-0865, Japan.

出版信息

J Pharm Sci. 2017 Aug;106(8):2046-2052. doi: 10.1016/j.xphs.2017.04.042. Epub 2017 Apr 27.

DOI:10.1016/j.xphs.2017.04.042
PMID:28456722
Abstract

Hepatic stellate cells (HSCs) are responsible for hepatic fibrosis and liver cirrhosis via their ability to produce extracellular matrices such as collagens and elastin. However, a strategy for delivering cargoes to HSCs has not been established yet. We herein report on attempts to deliver small interfering RNA (siRNA) to HSCs using several types of SS-cleavable proton-activated lipid-like materials (ssPalms) that contained myristic acid (ssPalmM) or hydrophobic vitamin A (ssPalmA) and E (ssPalmE) as hydrophobic scaffolds. We initially verified that hepatic fibrosis could induce the treatment with tetrachloromethane in terms of collagen fibrils and the expression of marker genes, type I collagen α-1, transforming growth factor β, heat shock protein 47, and α-smooth muscle actin. The siRNA silencing efficiency of the 3 LNPs was then compared using fibrosis-induced mice. Of the materials tested, LNP showed the highest efficiency, with an effective (ED)50 of approximately 0.25 mg siRNA/kg. The LNP showed a significant inhibitory effect on collagen production at a dose of 3.0 mg siRNA/kg with no evidence of any severe adverse effects. In conclusion, LNP holds considerable potential for use in the treatment of HSCs-mediated diseases.

摘要

肝星状细胞 (HSCs) 通过产生细胞外基质如胶原和弹性蛋白而导致肝纤维化和肝硬化。然而,尚未建立向 HSCs 递送载药的策略。我们在此报告了使用几种包含豆蔻酸 (ssPalmM) 或疏水性维生素 A (ssPalmA) 和 E (ssPalmE) 作为疏水性支架的 SS 可切割质子激活脂质类似物 (ssPalms) 将小干扰 RNA (siRNA) 递送至 HSCs 的尝试。我们最初验证了四氯化碳处理可以诱导胶原纤维和标记基因(I 型胶原α-1、转化生长因子β、热休克蛋白 47 和α-平滑肌肌动蛋白)的表达,从而诱导肝纤维化。然后使用诱导纤维化的小鼠比较了 3 种 LNPs 的 siRNA 沉默效率。在测试的材料中,LNP 的效率最高,ED50 约为 0.25 mg/kg siRNA。LNP 在 3.0 mg/kg siRNA 剂量下对胶原产生具有显著的抑制作用,没有任何严重不良反应的证据。总之,LNP 在治疗 HSCs 介导的疾病方面具有很大的潜力。

相似文献

1
The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material.采用由维生素 A 支架脂质类似物组成的脂质纳米颗粒向肝星状细胞递送小干扰 RNA。
J Pharm Sci. 2017 Aug;106(8):2046-2052. doi: 10.1016/j.xphs.2017.04.042. Epub 2017 Apr 27.
2
Inhibition of plasminogen activator inhibitor-1 expression by siRNA in rat hepatic stellate cells.小干扰RNA对大鼠肝星状细胞中纤溶酶原激活物抑制剂-1表达的抑制作用
J Gastroenterol Hepatol. 2008 Dec;23(12):1917-25. doi: 10.1111/j.1440-1746.2008.05485.x. Epub 2008 Aug 28.
3
Inhibitory effect of receptor for advanced glycation end product‑specific small interfering RNAs on the development of hepatic fibrosis in primary rat hepatic stellate cells.晚期糖基化终产物特异性小干扰RNA受体对原代大鼠肝星状细胞肝纤维化发展的抑制作用
Mol Med Rep. 2015 Jul;12(1):569-74. doi: 10.3892/mmr.2015.3342. Epub 2015 Feb 12.
4
Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis.脂质样纳米颗粒中I型前胶原α1小分子干扰RNA的特异性肝脏递送可缓解肝纤维化。
Hepatology. 2015 Oct;62(4):1285-97. doi: 10.1002/hep.27936. Epub 2015 Aug 28.
5
A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma.一种中性脂质包膜型纳米颗粒,由 pH 激活和维生素 E 支架脂质样材料组成,作为针对肾细胞癌的基因载体的平台。
J Control Release. 2015 Feb 28;200:97-105. doi: 10.1016/j.jconrel.2014.12.029. Epub 2014 Dec 24.
6
Gremlin1 Accelerates Hepatic Stellate Cell Activation Through Upregulation of TGF-Beta Expression.Gremlin1通过上调转化生长因子-β表达加速肝星状细胞激活。
DNA Cell Biol. 2017 Jul;36(7):603-610. doi: 10.1089/dna.2017.3707. Epub 2017 May 3.
7
New role and molecular mechanism of Gadd45a in hepatic fibrosis.Gadd45a在肝纤维化中的新作用及分子机制
World J Gastroenterol. 2016 Mar 7;22(9):2779-88. doi: 10.3748/wjg.v22.i9.2779.
8
NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis.NLRC5在肝纤维化过程中调节转化生长因子-β1诱导的肝星状细胞增殖和激活。
Int J Biochem Cell Biol. 2016 Jan;70:92-104. doi: 10.1016/j.biocel.2015.11.010. Epub 2015 Nov 26.
9
Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease.沉默胎盘生长因子可改善慢性肝病小鼠模型的肝纤维化和血管生成,并抑制肝星状细胞的活化。
J Cell Mol Med. 2017 Oct;21(10):2370-2385. doi: 10.1111/jcmm.13158. Epub 2017 Apr 5.
10
Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis.携带靶向 TIMP-1 的小干扰 RNA 的重组腺相关病毒对大鼠肝纤维化的抗纤维化作用。
Am J Pathol. 2013 May;182(5):1607-16. doi: 10.1016/j.ajpath.2013.01.036. Epub 2013 Mar 7.

引用本文的文献

1
Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism.脂质纳米颗粒为何靶向肝脏?对生物分布和肝脏特异性嗜性的理解。
Mol Ther Methods Clin Dev. 2025 Feb 15;33(1):101436. doi: 10.1016/j.omtm.2025.101436. eCollection 2025 Mar 13.
2
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.靶向慢性肝脏疾病:分子标志物、药物传递策略和未来展望。
Int J Pharm. 2024 Jul 20;660:124381. doi: 10.1016/j.ijpharm.2024.124381. Epub 2024 Jun 23.
3
RNA nanomedicine in liver diseases.
用于肝脏疾病的RNA纳米医学
Hepatology. 2025 Jun 1;81(6):1847-1877. doi: 10.1097/HEP.0000000000000606. Epub 2024 Aug 26.
4
Galangin delivered by retinoic acid-modified nanoparticles targeted hepatic stellate cells for the treatment of hepatic fibrosis.通过视黄酸修饰的纳米颗粒递送的高良姜素靶向肝星状细胞用于治疗肝纤维化。
RSC Adv. 2023 Apr 6;13(16):10987-11001. doi: 10.1039/d2ra07561j. eCollection 2023 Apr 3.
5
Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.小干扰RNA在胃肠道肿瘤中的潜在应用
Pharmaceuticals (Basel). 2022 Oct 20;15(10):1295. doi: 10.3390/ph15101295.
6
Lipids and Lipid Derivatives for RNA Delivery.用于 RNA 递送的脂质和脂质衍生物。
Chem Rev. 2021 Oct 27;121(20):12181-12277. doi: 10.1021/acs.chemrev.1c00244. Epub 2021 Jul 19.
7
Nuclear VEGFR-2 Expression of Hepatocytes Is Involved in Hepatocyte Proliferation and Liver Regeneration During Chronic Liver Injury.核 VEGFR-2 表达的肝细胞参与慢性肝损伤时的肝细胞增殖和肝再生。
In Vivo. 2021 May-Jun;35(3):1473-1483. doi: 10.21873/invivo.12400.
8
Recent advances in siRNA delivery mediated by lipid-based nanoparticles.脂质纳米粒介导的 siRNA 递呈的最新进展。
Adv Drug Deliv Rev. 2020;154-155:64-78. doi: 10.1016/j.addr.2020.07.022. Epub 2020 Aug 6.
9
siRNA- and miRNA-based therapeutics for liver fibrosis.基于 siRNA 和 miRNA 的肝纤维化治疗方法。
Transl Res. 2019 Dec;214:17-29. doi: 10.1016/j.trsl.2019.07.007. Epub 2019 Aug 13.
10
Hepatic Cellular Distribution of Silica Nanoparticles by Surface Energy Modification.通过表面能修饰实现的硅纳米颗粒的肝内细胞分布。
Int J Mol Sci. 2019 Aug 5;20(15):3812. doi: 10.3390/ijms20153812.